News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Meda AB (MDABF.PK) Acquires Exclusive Rights to New Treatment of Actinic Keratosis From Graceway Pharmaceuticals, LLC


5/12/2010 9:56:12 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Meda has acquired exclusive European rights to a new formulation of imiquimod from Graceway Pharmaceuticals. The new formulation is 3,75% imiquimod topical cream indicated for the treatment of actinic keratosis (AK). This product has recently been approved in the US and Canada.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES